e-ISSN: 2321-3647
logo

American Journal of Pharmacy and Health Research

📢 Latest Update: Call for Papers – Special Issue on Pharmacy and Health Research (April 2026 Submission Deadline)

📢 Latest Update: Call for Papers – Special Issue on Pharmacy and Health Research (April 2026 Submission Deadline)

Volume 13, Issue 10 - 2025 (October 2025 Issue 10)

Volume 13 Issue 10 Cover

Issue Details:

Volume 13 Issue 10
Published:Invalid Date

Editorial: October 2025 Issue 10

Welcome to the 2025 issue of American Journal of Pharmacy and Health Research. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr. Hemangi J Patel
Editor-in-Chief
American Journal of Pharmacy and Health Research

Articles in This Issue

Showing 1 of 1 articles
Research PaperID: AJPHR1310001

Dapagliflozin Induced Severe Pruritis – A Rare Adverse Drug Reaction

Dr. Namitha Rachel Biji, Prof. Dr. S.K Mathew, Dr. Dhanu Josey, Dr. Joseph John

ABSTRACTDapagliflozin is an SGLT2 inhibitor that is used to treat type 2 diabetes, as well as those with heart failure and chronic renal disease. We report a case report of a 57-year-old male diabetic who presented with severe pruritis which was later found to be due to dapagliflozin and was totally subsided after discontinuing dapagliflozin. Keyword: SGLT2 inhibitor - Selective sodium-glucose transporter-2 inhibitor.

SGLT2 inhibitor - Selective sodium-glucose transporter-2 inhibitor.
112,069 views
33,635 downloads

Contributors:

 Dr. Namitha Rachel Biji
,
 Prof. Dr. S.K Mathew
,
 Dr. Dhanu Josey
,
 Dr. Joseph John